NexImmune Inc (NEXI)
0.3235
+0.10
(+46.31%)
USD |
OTCM |
Nov 14, 15:14
NexImmune Enterprise Value: -2.116M for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | -2.116M |
| November 12, 2024 | -2.116M |
| November 11, 2024 | -2.075M |
| November 08, 2024 | -2.075M |
| November 07, 2024 | -2.075M |
| November 06, 2024 | -2.136M |
| November 05, 2024 | -2.136M |
| November 04, 2024 | -2.136M |
| November 01, 2024 | -2.116M |
| October 31, 2024 | -1.908M |
| October 30, 2024 | -2.121M |
| October 29, 2024 | -2.052M |
| October 28, 2024 | -2.052M |
| October 25, 2024 | -2.121M |
| October 24, 2024 | -2.121M |
| October 23, 2024 | -2.093M |
| October 22, 2024 | -2.067M |
| October 21, 2024 | -2.073M |
| October 18, 2024 | -1.964M |
| October 17, 2024 | -1.964M |
| October 16, 2024 | -1.978M |
| October 15, 2024 | -2.103M |
| October 14, 2024 | -2.048M |
| October 11, 2024 | -2.123M |
| October 10, 2024 | -2.096M |
| Date | Value |
|---|---|
| October 09, 2024 | -2.082M |
| October 08, 2024 | -2.111M |
| October 07, 2024 | -2.144M |
| October 04, 2024 | -2.142M |
| October 03, 2024 | -2.131M |
| October 02, 2024 | -2.089M |
| October 01, 2024 | -2.082M |
| September 30, 2024 | -2.075M |
| September 27, 2024 | -2.075M |
| September 26, 2024 | -2.006M |
| September 25, 2024 | -1.980M |
| September 24, 2024 | -2.061M |
| September 23, 2024 | -2.075M |
| September 20, 2024 | -2.075M |
| September 19, 2024 | -2.006M |
| September 18, 2024 | -2.002M |
| September 17, 2024 | -2.054M |
| September 16, 2024 | -1.982M |
| September 13, 2024 | -1.894M |
| September 12, 2024 | -1.894M |
| September 11, 2024 | -1.929M |
| September 10, 2024 | -1.928M |
| September 09, 2024 | -1.936M |
| September 06, 2024 | -1.907M |
| September 05, 2024 | -1.907M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-40.93M
Minimum
Mar 11 2022
651.27M
Maximum
Feb 26 2021
52.75M
Average
-2.142M
Median
Oct 04 2024
Enterprise Value Benchmarks
| CEL-SCI Corp | 38.36M |
| AIM ImmunoTech Inc | 7.900M |
| IGC Pharma Inc | 26.09M |
| NovaBay Pharmaceuticals Inc | 2.762M |
| Protalix BioTherapeutics Inc | 66.58M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.327M |
| Total Expenses (Quarterly) | 2.730M |
| EPS Diluted (Quarterly) | -1.69 |
| Earnings Yield | -5.73K% |